Retrophin (RTRX) Downgraded by BidaskClub

BidaskClub lowered shares of Retrophin (NASDAQ:RTRX) from a buy rating to a hold rating in a research note published on Friday.

A number of other equities research analysts have also weighed in on the company. Nomura began coverage on Retrophin in a research report on Monday, November 19th. They set a buy rating and a $57.00 target price for the company. Zacks Investment Research lowered Retrophin from a hold rating to a strong sell rating in a research report on Thursday, November 8th. ValuEngine raised Retrophin from a buy rating to a strong-buy rating in a research report on Wednesday, November 7th. Finally, Jefferies Financial Group began coverage on Retrophin in a research report on Tuesday, October 30th. They set a buy rating and a $44.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Retrophin has a consensus rating of Buy and an average target price of $48.00.

Shares of RTRX opened at $23.52 on Friday. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $951.99 million, a P/E ratio of -15.68 and a beta of 1.21. Retrophin has a fifty-two week low of $20.09 and a fifty-two week high of $33.00.

Retrophin (NASDAQ:RTRX) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.39). The firm had revenue of $40.70 million for the quarter, compared to the consensus estimate of $44.36 million. Retrophin had a negative net margin of 69.38% and a negative return on equity of 35.43%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the firm earned $0.15 earnings per share. Sell-side analysts expect that Retrophin will post -2.67 earnings per share for the current year.

In related news, insider William E. Rote sold 5,000 shares of the business’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $24.03, for a total transaction of $120,150.00. Following the transaction, the insider now directly owns 20,792 shares in the company, valued at approximately $499,631.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Neil F. Mcfarlane sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $23.73, for a total value of $237,300.00. Following the transaction, the chief operating officer now owns 29,476 shares in the company, valued at $699,465.48. The disclosure for this sale can be found here. Insiders sold a total of 68,611 shares of company stock worth $1,583,635 over the last quarter. Company insiders own 3.67% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Meeder Asset Management Inc. grew its stake in Retrophin by 315.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,663 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 3,541 shares during the last quarter. Sei Investments Co. purchased a new position in Retrophin during the 2nd quarter worth $141,000. Shell Asset Management Co. purchased a new position in Retrophin during the 3rd quarter worth $231,000. FNY Investment Advisers LLC grew its stake in Retrophin by 100.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 5,000 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Retrophin during the 3rd quarter worth $333,000.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: The risks of owning bonds

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply